BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24070162)

  • 1. Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Scuffham PA
    Health Qual Life Outcomes; 2013 Sep; 11():149. PubMed ID: 24070162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of health state utility values associated with oral potentially malignant disorders and oral cancer in Sri Lanka assessed using the EQ-5D-3 L and the EORTC-8D.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    Health Qual Life Outcomes; 2016 Jul; 14():101. PubMed ID: 27402015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EQ-5D-3L derived population norms for health related quality of life in Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    PLoS One; 2014; 9(11):e108434. PubMed ID: 25365171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing EQ-5D health states for Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    Qual Life Res; 2015 Jul; 24(7):1785-93. PubMed ID: 25543271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an EORTC-8D utility algorithm for Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    Med Decis Making; 2015 Apr; 35(3):361-70. PubMed ID: 25403654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
    Kularatna S; Chen G; Byrnes J; Scuffham PA
    Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
    Rowen D; Young T; Brazier J; Gaugris S
    Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.
    Kularatna S; Senanayake S; Gunawardena N; Graves N
    BMJ Open; 2019 Feb; 9(2):e024854. PubMed ID: 30772857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity and internal consistency of EQ-5D-3L quality of life tool among pre-dialysis patients with chronic kidney disease in Sri Lanka, a lower middle-income country.
    Senanayake S; Mahesh PKB; Gunawardena N; Graves N; Kularatna S
    PLoS One; 2019; 14(6):e0211604. PubMed ID: 31242189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.
    Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P
    Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
    Lorgelly PK; Doble B; Rowen D; Brazier J;
    Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D Multi-Attribute Utility Instruments in Patients Who Have Previously Undergone Bariatric Surgery.
    Campbell JA; Palmer AJ; Venn A; Sharman M; Otahal P; Neil A
    Patient; 2016 Aug; 9(4):311-22. PubMed ID: 26841910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions.
    Kularatna S; Byrnes J; Chan YK; Carrington MJ; Stewart S; Scuffham PA
    Int J Cardiol; 2017 Jan; 227():172-176. PubMed ID: 27865116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
    Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
    Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.